AAV technology

Discover AAVENZENE, a toolkit for gene therapy, and deliver DNA to target cells.

What is AAVENZENE?

Adeno-associated virus (AAV) is a versatile viral vector used as a mechanism of delivery in gene therapy. AAVs are easily adaptable and can be engineered to specifically deliver DNA to target cells.

To develop gene therapies, recombinant AAV (rAAV), which lacks any viral DNA, is used. The use of rAAV in clinical and preclinical applications has proven a safe and effective delivery system. In addition to gene therapy applications, rAAV particles can also be used in in vitro transcription (IVT).

Our AAVENZENE kit includes the essential tools you need to produce your desired rAAV particles, including:

AAV RepCap plasmid
AAV helper plasmid
AAV expression plasmid suitable for cloning the gene of interest (GOI)

Each plasmid encodes key components required to prepare rAAV particles. After the three plasmid (triple) transfection method, the components are expressed and the rAAV particles are produced.

A positive control is also provided with yellow fluorescent protein (YFP) as the GOI.

Why partner with Enzene?

We are a global Continuously Innovative Development and Manufacturing Organization (CIDMO), dedicated to changing the paradigm by which affordable biologic and biosimilar medicines are brought to market. Since Enzene’s inception, our innovative agility has enabled us to continually introduce transformative processes in biologics manufacturing that significantly increase product yields of complex biologics and monoclonal antibodies (mAbs) while reducing the manufacturing footprint and the cost of production.

Game-changing innovation is only the beginning, though. We are Enzene, and that means that our values of innovation, entrepreneurship, respect, candor, excellence, and integrity underscore everything we do from project management and communications to teamwork and ideation. To us, true partnership is about driving biotech innovation while doing so in a way that develops long-lasting trusted partnerships.